Compare Eli Lilly And Co (LLY) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs S&P500 ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while S&P500 ETF trades at $778.54 (market cap $821.54B). The key difference: Eli Lilly And Co is the larger of the two by market cap, and Eli Lilly And Co pays a 0.59% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and S&P500 ETF for 205 Days on average.
| LLY | SPY | |
|---|---|---|
Market Cap | $1.04T | $821.54B |
Volume | 3,064,878 | 40,070,358 |
Sector | Health | — |
52-Week High | $1.28K | $779.14 |
52-Week Low | $799.57 | $631.99 |
Typical Hold Time | 93 Days | 205 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
SPY, the SPDR S&P 500 ETF, trades at $778.54, up 0.16% on the day, with a bullish technical signal driven by moving averages. The ETF is positioned near resistance at $777, with support at $771. Recent news highlights mixed sentiment, with some articles noting strong profit growth expectations for the S&P 500 in 2026 but potential headwinds from margin debt and slowing growth forecasts for 2027.
The outlook for SPY remains tied to broader market trends, with opportunities from potential year-end rallies and strong corporate earnings, but risks include macroeconomic volatility and elevated valuations. Investor sentiment is cautious amid warnings about market collapses and shifting profit growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
